Company Directory / Pharmaceuticals
Public · LSE:OXBFor profitPharmaceuticalsOxford, Oxfordshire, United Kingdom
Oxford BioMedica
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research.
- Founded
- 1995 31 years ago
- Staff
- 501-1000 833 on LinkedIn
- Followers
- 47k on LinkedIn
- Funding
- $116M as listed, USD
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies,… Read all
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
Set against six million companies
Size
501-1000 people: larger than 95% of companies with a size listed. 833 people list it on LinkedIn.
Age
31 years old.
Reach
Website ranked #2,805,420 in the world for traffic, about 6k visits a month. 46,922 followers on LinkedIn.
What it does
BiotechnologyGeneticsTherapeuticsGene therapyImmunotherapyViral vector GMP manufacturingCell and gene therapyLentiviral VectorsAAVCell therapyCDMOGMPProcess DevelopmentManufacturingAdvanced Therapies
Funding, as listed
$116M raised in total
- Rounds5
- LatestPost ipo equity, Sept 2021
- Latest amountUSD 68,081,491
- Investors3, 1 leading
What the source datasets report. We have not watched these rounds ourselves, and do not hold this company in the startups database.
Funding filed with regulators
Oxford BioMedica filed 3 raises, $81M in all. Filings say how much was sold and to how many investors; they never name the investors.
- Dec 2025$137KUK share allotment
- Dec 2025$256KUK share allotment
- Aug 2025$81MUK share allotment
Every detail we hold
Everything the source datasets list about Oxford BioMedica, field by field. Contact details are held but never shown.
The company
- Name
- Oxford BioMedica
- Type
- For profit
- Status
- Public · LSE:OXB
- Founded
- 1995
- Founders
- Alan Kingsman, Susan Kingsman
- Industry
- Pharmaceuticals
- Categories
- Biotechnology, Genetics, Therapeutics
- Specialities
- Gene therapy, Immunotherapy, Viral vector GMP manufacturing, Cell and gene therapy, Lentiviral Vectors, AAV, Cell therapy, CDMO, GMP, Process Development, Manufacturing, Advanced Therapies
Where
- City
- Oxford
- Region
- Oxfordshire
- Country
- United Kingdom
- Markets
- Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 501-1000
- People on LinkedIn
- 833
- LinkedIn followers
- 46,922
- Web traffic rank
- #2,805,420
- Monthly web visits
- 6,024
Funding, as listed
- Total
- $115,800,000 USD
- Rounds
- 5
- Latest round
- Post ipo equity
- Latest round date
- Sept 2021
- Latest amount
- 68,081,491 USD
- Investors
- 3
- Lead investors
- 1
- Stock listing
- LSE:OXB
- Listing status
- public
Corporate family
- Acquisitions made
- 1
About this record
- Sources
- Crunchbase, LinkedIn
- Last imported
- Sept 2026
Growth, as the source summarises it
Oxford Biomedica completed the acquisition of ABL Europe. However, investors have experienced a 71% loss over the past three years, and the company missed its full-year 2023 earnings expectations.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
Pharmaceuticals in United Kingdom.
Ferring Controlled TherapeuticsEast Kilbride · 5001-10000 people · 1k followers
Redx PharmaAlderley Park · 51-100 people · 12k followers
Archimedes PharmaReading · 51-100 people · 4k followersCCellZome51-100 people · 2k followers
EUSA PharmaHemel Hempstead · 51-100 people · 14k followersFrom the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 372,993 companies in United Kingdom and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.